Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Vorolanib (X-82) is a dual VEGFR/PDGFR inhibitor, which inhibits tumor angiogenesis and cell proliferation in tumors (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2588-2588).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Vorolanib||X-82|CM-082|CM082||PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 32||Vorolanib (X-82) is a dual VEGFR/PDGFR inhibitor, which inhibits tumor angiogenesis and cell proliferation in tumors (PMID: 32335374, PMID: 30478190).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Vorolanib||Phase I||Actionable||In a Phase I trial, Vorolanib (X-82) was well tolerated and demonstrated preliminary efficacy, resulting in a complete response in 2% (1/49), a partial response in 2% (1/49), and stable disease in 51% (25/49) of patients with advanced solid tumors, with a median progression-free survival of 2 months (PMID: 30478190; NCT01296581).||30478190|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01296581||Phase I||Vorolanib||Safety Study of X-82 in Patients With Advanced Solid Tumors||Completed||USA||0|